Jad G. Sfeir

Jad G. Sfeir

Auto-generated profile, based on publicly available information

Jad G. Sfeir

Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester , Rochester, MN 55905

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JFJoshua N Farr
Joshua N Farr
MXMing Xu
Ming Xu
MWMegan M Weivoda
Megan M Weivoda
DMDavid G Monroe
David G Monroe
DFDaniel G Fraser
Daniel G Fraser
SKSundeep Khosla
Sundeep Khosla
Genetic or pharmacological depletion of senescent cells or inhibition of their function reduces bone loss in aged mice. Aging is associated with increased cellular senescence, which is hypothesized to drive the eventual development of multiple comorbidities1. Here we investigate a role for senescent cells in age-related bone loss through multiple approaches. In particular, we used either genetic (i.e., the INK-ATTAC 'suicide' transgene encoding an inducible caspase 8 expressed specifically in senescent cells2,3,4) or pharmacological (i.e., 'senolytic' compounds5,6) means to eliminate senescent cells. We also inhibited the production of the proinflammatory secretome of senescent cells using a JAK inhibitor (JAKi)3,7. In aged (20- to 22-month-old) mice with established bone loss, activation of the INK-ATTAC caspase 8 in senescent cells or treatment with senolytics or the JAKi for 2–4 months resulted in higher bone mass and strength and better bone microarchitecture than in vehicle-treated mice. The beneficial effects of targeting senescent cells were due to lower bone resorption with either maintained (trabecular) or higher (cortical) bone formation as compared to vehicle-treated mice. In vitro studies demonstrated that senescent-cell conditioned medium impaired osteoblast mineralization and enhanced osteoclast-progenitor survival, leading to increased osteoclastogenesis. Collectively, these data establish a causal role for senescent cells in bone loss with aging, and demonstrate that targeting these cells has both anti-resorptive and anabolic effects on bone. Given that eliminating senescent cells and/or inhibiting their proinflammatory secretome also improves cardiovascular function4, enhances insulin sensitivity3, and reduces frailty7, targeting this fundamental mechanism to prevent age-related bone loss suggests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbidities.

2 July 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JFJoshua Nicholas Farr
Joshua Nicholas Farr
EAElizabeth J. Atkinson
Elizabeth J. Atkinson
SASara J. Achenbach
Sara J. Achenbach
TVTammie L. Volkman
Tammie L. Volkman
ATAmanda J. Tweed
Amanda J. Tweed
SKSundeep Khosla
Sundeep Khosla

1 June 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
JSJad G. Sfeir
Jad G. Sfeir
MDMatthew T. Drake
Matthew T. Drake
SKSundeep Khosla
Sundeep Khosla
JFJoshua Nicholas Farr
Joshua Nicholas Farr

30 July 2025 in BMJ
Verified
Journal Article
Open access
PDF file
CHCaroline Wei Shan Hoong
Caroline Wei Shan Hoong
DSDominik Saul
Dominik Saul
SKSundeep Khosla
Sundeep Khosla
JSJad G Sfeir
Jad G Sfeir
Osteoporosis is a chronic disease mainly prevalent in older people. A hip fracture, its most devastating complication, is associated with a one in five chance of mortality in the first year. This review discusses emerging risk factors for bone fragility including diabetes, sarcopenia, and bariatric surgery. Recency of fracture represents an imminent risk that deserves prompt recognition. The new FRAXplus calculator accounts for additional risk factors to refine existing risk stratification. Advances in imaging techniques such as trabecular bone score and radiofrequency echographic multi-spectrometry may have potential roles in specific populations. Treatment of osteoporosis requires a multifaceted approach. Non-drug interventions include fall prevention and resistance exercises, supplementation with calcium, vitamin D and possibly vitamin K, and effective bridging of care gaps with fracture liaison services. An overview of drug therapy is provided, drawing attention to the importance of sequential therapy starting with potent anabolic agents for the patients at the highest risk, as opposed to a traditional step-up approach. An individualized, goal directed care plan is necessary for a treat-to-target approach, with total hip bone mineral density being the best specific target. Future research in cellular senescence points to the role of senolytics and senomorphics to alleviate osteoporosis, among other age related conditions.

29 June 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
STShrikant Tamhane
Shrikant Tamhane
JSJad G Sfeir
Jad G Sfeir
NKNana Esi N Kittah
Nana Esi N Kittah
SJSina Jasim
Sina Jasim
WCWassim Chemaitilly
Wassim Chemaitilly
MMM Hassan Murad
M Hassan Murad
Background: GH deficiency (GHD) is common among childhood cancer survivors (CCSs) with history of tumors, surgery, and/or radiotherapy involving the hypothalamus-pituitary region. We aimed to evaluate the effects of GH therapy (GHT) in CCSs on adult height, risk of diabetes mellitus, abnormal lipids, metabolic syndrome, quality of life, secondary tumors, and disease recurrence. Methods: We searched multiple databases for randomized and observational studies. Pairs of reviewers independently selected studies and collected data. Random effects meta-analysis was used to pool outcomes across the studies. Results: We included 29 observational studies at moderate to high risk of bias. Sixteen studies compared CCSs on GHT with those not on GHT (512 patients, GH dose: 0.3 to 0.9 IU/kg/week). GHT was significantly associated with height gain [standard deviation score, 0.61; 95% CI, 0.08 to 1.13] and was not significantly associated with the occurrence of secondary tumors [odds ratio (OR), 1.10; 95% CI, 0.72 to 1.67] or tumor recurrence (OR, 0.57; 95% CI, 0.31 to 1.02). Thirteen studies compared CCSs on GHT with normal age- or sex-matched controls or controls with idiopathic GHD or short stature. GHT was associated with either improved or unchanged risk of diabetes, lipid profiles, and metabolic syndrome. GHT was associated with improvements in quality of life. Conclusion: CCSs treated with GHT gain height compared with the untreated controls. GHT may improve lipid profiles and quality of life and does not appear to increase the risk of diabetes or the development of secondary tumors, although close monitoring for such complications remains warranted due to uncertainty in the current evidence.

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
SBSigridur Bjornsdottir
Sigridur Bjornsdottir
SISteven Ing
Steven Ing
DMDeborah M Mitchell
Deborah M Mitchell
TSTanja Sikjaer
Tanja Sikjaer
LULine Underbjerg
Line Underbjerg
BLBart L Clarke L
Bart L Clarke L
Chronic hypoparathyroidism is characterized by low serum calcium, increased serum phosphorus, and inappropriately low or decreased serum parathyroid hormone. This rare disorder is associated with a variety of complications. The prevalence, incidence, mortality, financial burden, and epidemiology of complications of this disorder are not well understood. This narrative review summarizes current information on the epidemiology and complications of chronic hypoparathyroidism. The reported prevalence of chronic hypoparathyroidism ranges from 6.4–37/100,000, and the incidence is reported to be 0.8–2.3/100,000/year. Mortality is not increased in studies from Denmark or South Korea but was increased in studies from Scotland and Sweden. The financial burden of this disorder is substantial because of increased health care resource utilization in two studies but not well quantitated. Recognized complications include hypercalciuria, nephrocalcinosis, kidney stones, and chronic kidney disease; low bone turnover and possibly upper extremity fractures; cardiac and vascular calcifications; basal ganglia calcifications, cataracts, infections, neuropsychiatric complications, and difficulties with pregnancy. This review concludes that chronic hypoparathyroidism is a rare disorder associated with significant morbidity that may not increase overall mortality but is associated with a substantial financial burden. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).